Business
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK (LSE/NYSE: GSK). This strategic move secures Samsung Biologics' first U.S.-based manufacturing site, a significant expansion of the company's global footprint and its long-term commitment to the U.S. market.
About this update from Samsung Biologics Co., Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs","length":170,"tagName":"p"}]},{"val":[{"type":"text","content":"Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain","length":111,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":400,"olType":false},{"type":"text","content":"INCHEON, South Korea, ROCKVILLE, Md. and LONDON , Dec. 21, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK (LSE/NYSE: GSK). This strategic move secures Samsung Biologics' first U.S.-based manufacturing site, a significant expansion of the company's global footprint and its long-term commitment to the U.S. market.","length":578,"tagName":"p"},{"type":"image","alt":"Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK","displaySize":"","headline":null,"caption":"Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/a337e63fba05247f9984982101a1b7ca"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a6.oNOr8CR5gNW_ENaLXjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a337e63fba05247f9984982101a1b7ca","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2850103/Image__Samsung_Biologics_Expands_U_S__Manufacturing_Capabilities.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Located in Rockville, Maryland, the facility sits at the center of one of the key U.S. bio-clusters and encompasses two cGMP manufacturing plants with a combined 60,000 liters of drug...